- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05540964
An Antiretroviral Treatment Interruption (ATI) Study to Evaluate the Impact of Genetically Modified Autologous Cells (AGT103-T) to Suppress Human Immunodeficiency Virus Replication in the Absence of Antiretroviral Therapy
An Antiretroviral Treatment Interruption(ATI) Study to Evaluate the Impact and Durability of AGT103-T to Suppress Human Immunodeficiency Virus Replication in the Absence of Antiretroviral Therapy(ART) in Participants With Human Immunodeficiency Virus(HIV) Previously Treated With AGT103-T
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Study Type
Enrollment (Anticipated)
Contacts and Locations
Study Locations
-
-
District of Columbia
-
Washington, District of Columbia, United States, 20007
- Georgetown University
-
Washington, District of Columbia, United States, 20017
- Washington Health Institute
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
Successful engraftment of AGT103-T with at least 30 days post-infusion safety monitoring during the AGT-HC-168 Parent Study.
Note: Successful engraftment is defined as detectable levels of AGT103-T cells bearing the AGT103 lentivirus vector.
- HIV <50 copies of viral RNA/mL plasma on stable ART.
- Continuation on the same ART regimen during the AGT-HC-168 Parent Study unless change in treatment with ART regimen is medically indicated.
- CD4 T cell count >400 cells/mm3.
- Ability to understand the study and willingness to comply with study-required procedures and visits.
- Written informed consent signed and dated by the study participant.
- A negative pregnancy test for females of childbearing potential. A female participant is considered to be of childbearing potential if she is menstruating, has an intact uterus and at least 1 ovary, and is less than 2 years postmenopausal.
- Unless medically prescribed, a negative drug test for amphetamines; barbiturates; benzodiazepines; cocaine; methadone (Dolophine®); opiates (codeine, morphine only); phencyclidine (PCP); propoxyphene.
- Female participants of childbearing potential and male participants who are sexually active with a partner of childbearing potential must agree to use an adequate method of contraception at screening and throughout trial participation.
- Female and male participants who are sexually active with a partner must agree to abstain from sexual activity or use an adequate method of protection (e.g., condoms) at screening and throughout trial participation.
Agree to not receive immunosuppressive and/or investigational therapies during the study.
Note: Prohibited immunosuppressive medications do not include corticosteroid nasal spray or inhaler; topical corticosteroids for mild, uncomplicated dermatitis; or oral/parenteral corticosteroids given for non-chronic conditions.
Has adequate organ function as indicated by the following laboratory values:
- Hematocrit ≥33% or hemoglobin ≥13 g/dL (males) and ≥12 g/dL (females)
- Platelet count ≥150,000/mm3
- Absolute neutrophil count ≥1,500/mm3
- Serum creatinine ≤1.3 times ULN or calculated creatinine clearance (for those with creatinine >1.3 ULN) ≥60 mL/min
- Prothrombin Time or INR ≤ 1.5 times ULN
- Total bilirubin <1.5 times the ULN range. If total bilirubin is elevated, direct bilirubin must be < 2 times the ULN range, except in participants with Gilbert's Syndrome who must have serum bilirubin <3.0 times ULN (NOTE: If participant is on an atazanavir containing therapy then a direct bilirubin should be measured instead of the total bilirubin and must be ≤ 1.0 mg/dL. Also, asymptomatic elevations due to ART medications are not exclusionary when, in the opinion of the Investigator, the abnormalities are not attributable to intrinsic hepatic disease.
- Amylase < 3.0 times ULN at the time of screening
- AST (SGOT) and ALT (SGPT): ≤ 3.0 times ULN
Exclusion Criteria
- Any Grade 3 or higher drug product-related AE in the AGT-HC-168 Parent Study (participant may be enrolled once AE resolved).
- Any change in health status that would exclude enrollment in the AGT-HC-168 Parent Study.
Active viral hepatitis B or hepatitis C infection. A complete hepatitis B virus (HBV) screen (B core antibody, HBV surface antibody, and HBV surface antigen testing) must be completed. Viral load testing will be used in questionable cases, per the discretion of the Investigator.
- The results for hepatitis B may be positive for surface antibodies against HBV but must be negative for circulating HBV surface antigen to confirm the absence of active infection.
- The results for hepatitis C virus (HCV) may be positive for antibodies against HCV but must be negative for HCV viral RNA in blood to confirm the absence of active infection.
- History of or current cancer or malignancy, with the exception of successfully treated basal cell carcinoma of the skin.
- Current diagnosis of New York Heart Association Grade 3 or 4 congestive heart failure, uncontrolled angina, or arrhythmias.
- Any clinically significant renal, hepatic, or pulmonary disease.
- Is being treated for culture-confirmed bacteremia or had culture-confirmed bacteremia within 1 month prior to screening.
- Has signs or symptoms of acute infectious disease.
- Significant laboratory values and/or chronic medical condition that in the opinion of the Principal Investigator could impact trial participation.
- Currently pregnant or breast-feeding.
- Unwilling to use acceptable methods of birth control from the time of study entry to 1 month after restart of ART if sexually active with opposite sex. The following are acceptable methods of birth control: condoms (male or female) with or without a spermicidal agent, intrauterine device, diaphragm or cervical cap with spermicide, or hormonal-based contraception.
- Active alcohol use or dependence that, in the opinion of the Investigator, would interfere with adherence to study requirements.
- Serious illness requiring systemic treatment and/or hospitalization within 30 days prior to screening.
- Subject is unwilling to agree to practice safe sex or share needles.
Study Plan
How is the study designed?
Design Details
- Observational Models: Case-Control
- Time Perspectives: Prospective
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
Single group
Study participants will be taken off antiretroviral therapy and blood samples will be collected during each clinic visit.
|
Study participant that were previously infused with autologous genetically modified cell product will be taken off ART and followed closely by monitoring HIV rebound.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
HIV kinetics
Time Frame: 3 Years
|
Observe for changes in the HIV viral load.
|
3 Years
|
CD T cell changes
Time Frame: 3year
|
Observe the changes in the CD4 T cells and CD8 T cells count following antiretroviral treatment interruption(ATI)
|
3year
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Assess the durability of AGT103-T gene-modified cells during and after ATI
Time Frame: 3 Year
|
Measure the AGT103-T gene-modified cell during and after ATI
|
3 Year
|
CD T cells changes
Time Frame: 3 Years
|
Measure changes in frequency of Gag-specific CD4 and CD8 T cells following ATI
|
3 Years
|
Collaborators and Investigators
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- RNA Virus Infections
- Virus Diseases
- Infections
- Blood-Borne Infections
- Communicable Diseases
- Sexually Transmitted Diseases, Viral
- Sexually Transmitted Diseases
- Lentivirus Infections
- Retroviridae Infections
- Immune System Diseases
- Slow Virus Diseases
- HIV Infections
- Acquired Immunodeficiency Syndrome
- Immunologic Deficiency Syndromes
- Anti-Infective Agents
- Antiviral Agents
- Anti-Retroviral Agents
Other Study ID Numbers
- AGT-HC-169
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on HIV
-
University of Alabama at BirminghamMobile County Health Deparment; Alabama Department of Public HealthRecruitingHIV | HIV Testing | HIV Linkage to Care | HIV TreatmentUnited States
-
ANRS, Emerging Infectious DiseasesHopital Universitaire Robert-Debre; Institut de Recherche pour le Developpement and other collaboratorsUnknownHIV | HIV-uninfected Children | Children Exposed to HIVCameroon
-
French National Agency for Research on AIDS and...Elizabeth Glaser Pediatric AIDS FoundationCompletedPartner HIV Testing | Couple HIV Counseling | Couple Communication | HIV IncidenceCameroon, Dominican Republic, Georgia, India
-
University of MinnesotaWithdrawnHIV Infections | HIV/AIDS | Hiv | AIDS | Aids/Hiv Problem | AIDS and InfectionsUnited States
-
CDC FoundationGilead SciencesUnknownHIV Preexposure Prophylaxis | HIV ChemoprophylaxisUnited States
-
Africa Health Research InstituteLondon School of Hygiene and Tropical Medicine; University College, London; University... and other collaboratorsRecruiting
-
Massachusetts General HospitalNational Institute of Mental Health (NIMH); Fenway Community Health; Tuberculosis...CompletedHIV/STI Risk | HIV/STI IncidenceUnited States, India
-
Hospital Clinic of BarcelonaCompletedIntegrase Inhibitors, HIV; HIV PROTEASE INHIBSpain
-
Erasmus Medical CenterNot yet recruitingHIV Infections | Hiv | HIV-1-infection | HIV I InfectionNetherlands
-
University of WashingtonNational Institute of Mental Health (NIMH)RecruitingHIV Prevention | HIV Preexposure Prophylaxis | ImplementationKenya
Clinical Trials on Antiretroviral Therapy Interruption(ATI)
-
Hospital Clinic of BarcelonaCompletedHIV-Associated Lipodystrophy SyndromeSpain
-
ANRS, Emerging Infectious DiseasesRecruiting
-
Rockefeller UniversityNational Institute of Allergy and Infectious Diseases (NIAID); Montefiore Medical... and other collaboratorsCompleted
-
Objectif Recherche Vaccins SIDAFondation Bettencourt-SchuellerCompleted
-
ETOP IBCSG Partners FoundationAlliance for Clinical Trials in Oncology; Canadian Cancer Trials Group; Breast...Active, not recruitingEarly Breast CancerKorea, Republic of, United States, France, Canada, Spain, Lebanon, Belgium, Switzerland, Israel, Ireland, Japan, Italy, Denmark, Austria, Australia, Greece, Hungary, Netherlands, Norway, Portugal, Serbia, Slovenia
-
National Institute of Allergy and Infectious Diseases...WithdrawnHIV InfectionsUnited States, Puerto Rico
-
National Institute of Allergy and Infectious Diseases...Withdrawn
-
University of MinnesotaNational Heart, Lung, and Blood Institute (NHLBI)Completed
-
Centers for Disease Control and PreventionThe AIDS Support Organization; British Medical Research CouncilCompleted
-
Rockefeller UniversityAaron Diamond AIDS Research CenterCompletedHIV InfectionsUnited States